DGIdb - AZD-1480 Drug Record

AZD-1480 chembl:CHEMBL1231124 Antineoplastic

Alternate Names:

AZD1480
AZD-1480
AZD 1480

Drug Info:

Drug Class	Kinase Inhibitors

(3 More Sources)

Publications:

Deshpande et al., 2012, Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms., Leukemia
Ioannidis et al., 2011, Discovery of 5-chloro-N2-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (AZD1480) as a novel inhibitor of the Jak/Stat pathway., J. Med. Chem.
Hou S et al., 2014, Novel carbazole inhibits phospho-STAT3 through induction of protein-tyrosine phosphatase PTPN6., J Med Chem
Couto et al., 2012, AZD1480 blocks growth and tumorigenesis of RET- activated thyroid cancer cell lines., PLoS ONE

AZD-1480 STAT5A

Interaction Score: 9.47

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21138246

Sources:
DTC
AZD-1480 STAT3

Interaction Score: 1.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21138246 24978112

Sources:
DTC
AZD-1480 JAK2

Interaction Score: 0.73

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical

Response Type resistant

PMIDs:
21926964

Sources:
JAX-CKB TTD MyCancerGenome GuideToPharmacology ChemblInteractions
AZD-1480 JAK1

Interaction Score: 0.57

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? True

Endogenous Drug? False

Specific Action of the Ligand Inhibition

PMIDs:
None found

Sources:
MyCancerGenome GuideToPharmacology
AZD-1480 RET

Interaction Score: 0.27

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type thyroid medullary carcinoma

Response Type sensitive

Approval Status Preclinical - Cell culture

PMIDs:
23056499

Sources:
JAX-CKB
AZD-1480 JAK3

Interaction Score: 0.17

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

PMIDs:
None found

Sources:
GuideToPharmacology

MyCancerGenome: AZD1480
- Version: 20-Jun-2017
Alternate Names:

AZD1480 Development Name

Drug Info:

Drug Class Kinase Inhibitors

Publications:

DTC: AZD-1480

Version: 02-September-2020

Alternate Names:

CHEMBL1231124 ChEMBL Drug ID

Drug Info:

Publications:

Ioannidis et al., 2011, Discovery of 5-chloro-N2-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (AZD1480) as a novel inhibitor of the Jak/Stat pathway., J. Med. Chem.

Hou S et al., 2014, Novel carbazole inhibits phospho-STAT3 through induction of protein-tyrosine phosphatase PTPN6., J Med Chem

JAX-CKB: AZD1480

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Deshpande et al., 2012, Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms., Leukemia

Couto et al., 2012, AZD1480 blocks growth and tumorigenesis of RET- activated thyroid cancer cell lines., PLoS ONE

TTD: AZD1480
- Version: 2020.06.01
Alternate Names:

D0MP0X TTD Drug ID

Drug Info:

Publications:
GuideToPharmacology: 178102556
- Version: 29-September-2020
Alternate Names:

AZD1480 GuideToPharmacology Ligand Name

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1231124
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL1231124
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:

Evidence Type	Actionable
Approval Status	Preclinical
Response Type	resistant

Direct Interaction?	True
Endogenous Drug?	False
Specific Action of the Ligand	Inhibition

Indication/Tumor Type	thyroid medullary carcinoma
Response Type	sensitive
Approval Status	Preclinical - Cell culture

AZD-1480 Drug Record

AZD-1480 chembl:CHEMBL1231124 Antineoplastic

Alternate Names:

Drug Info:

Publications:

AZD-1480 STAT5A

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21138246

Sources: DTC

AZD-1480 STAT3

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21138246 24978112

Sources: DTC

AZD-1480 JAK2

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Evidence Type Actionable Approval Status Preclinical Response Type resistant

PMIDs: 21926964

Sources: JAX-CKB TTD MyCancerGenome GuideToPharmacology ChemblInteractions

AZD-1480 JAK1

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction? True Endogenous Drug? False Specific Action of the Ligand Inhibition

PMIDs: None found

Sources: MyCancerGenome GuideToPharmacology

AZD-1480 RET

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type thyroid medullary carcinoma Response Type sensitive Approval Status Preclinical - Cell culture

PMIDs: 23056499

Sources: JAX-CKB

AZD-1480 JAK3

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Specific Action of the Ligand Inhibition Endogenous Drug? False Direct Interaction? False

PMIDs: None found

Sources: GuideToPharmacology

MyCancerGenome: AZD1480

Alternate Names: AZD1480 Development Name

Drug Info: Drug Class Kinase Inhibitors

Publications:

DTC: AZD-1480

Alternate Names: CHEMBL1231124 ChEMBL Drug ID

Drug Info:

JAX-CKB: AZD1480

Alternate Names:

Drug Info:

Publications: Deshpande et al., 2012, Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms., Leukemia Couto et al., 2012, AZD1480 blocks growth and tumorigenesis of RET- activated thyroid cancer cell lines., PLoS ONE

TTD: AZD1480

Alternate Names: D0MP0X TTD Drug ID

Drug Info:

Publications:

GuideToPharmacology: 178102556

Alternate Names: AZD1480 GuideToPharmacology Ligand Name

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL1231124

Alternate Names:

Drug Info:

Publications:

ChemblInteractions: CHEMBL1231124

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

n/a

PMIDs:
21138246

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
21138246 24978112

Sources:
DTC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical

Response Type resistant

PMIDs:
21926964

Sources:
JAX-CKB TTD MyCancerGenome GuideToPharmacology ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? True

Endogenous Drug? False

Specific Action of the Ligand Inhibition

PMIDs:
None found

Sources:
MyCancerGenome GuideToPharmacology

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type thyroid medullary carcinoma

Response Type sensitive

Approval Status Preclinical - Cell culture

PMIDs:
23056499

Sources:
JAX-CKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

PMIDs:
None found

Sources:
GuideToPharmacology

Alternate Names:

AZD1480 Development Name

Drug Info:

Drug Class Kinase Inhibitors

Alternate Names:

CHEMBL1231124 ChEMBL Drug ID

Publications:

Deshpande et al., 2012, Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms., Leukemia

Couto et al., 2012, AZD1480 blocks growth and tumorigenesis of RET- activated thyroid cancer cell lines., PLoS ONE

Alternate Names:

D0MP0X TTD Drug ID

Alternate Names:

AZD1480 GuideToPharmacology Ligand Name